Expression and Efficient One-Step Chromatographic Purification of a Soluble Antagonist for Human Leukemia Inhibitory Factor Receptor in Escherichia coli
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Leukemia inhibitory factor (LIF) is a member of the IL-6 cytokine family, having pleiotropic actions such as maintaining stem cell pluripotency and enabling blastocyst implantation. Because the action of LIF is mediated by a ligand-receptor interaction with the LIF receptor (LIF-R), an antagonist for LIF-R has been developed to inhibit LIF-induced signaling. In this study, we present a novel method for the production and purification of an antagonist to human LIF-R (hLA). His-tagged hLA was expressed in E. coli, and simple purification methods without any endopeptidase cleavage were designed. In addition, we determined the optimal temperature conditions for enhancing the production of soluble hLA. Finally, the bioactivity of His-tagged hLA was examined using STAT3 phosphorylation and receptivity of human endometrial ECC-1 cells. Our strategy provides a rapid and efficient method to produce biologically active recombinant hLA.
Abstract
Leukemia inhibitory factor (LIF) is a member of the IL-6 cytokine family, having pleiotropic actions such as maintaining stem cell pluripotency and enabling blastocyst implantation. Because the action of LIF is mediated by a ligand-receptor interaction with the LIF receptor (LIF-R), an antagonist for LIF-R has been developed to inhibit LIF-induced signaling. In this study, we present a novel method for the production and purification of an antagonist to human LIF-R (hLA). His-tagged hLA was expressed in E. coli, and simple purification methods without any endopeptidase cleavage were designed. In addition, we determined the optimal temperature conditions for enhancing the production of soluble hLA. Finally, the bioactivity of His-tagged hLA was examined using STAT3 phosphorylation and receptivity of human endometrial ECC-1 cells. Our strategy provides a rapid and efficient method to produce biologically active recombinant hLA.
참고문헌 (28)
- Aschenbach LC, "The LIF receptor antagonist PEGLA is effectively delivered to the uterine endometrium and blocks LIF activity in cynomolgus monkeys", Contraception, 87, pp.813~823 (2013)
- Berkmen M., "Production of disulfide-bonded proteins in Escherichia coli", Protein Expr. Purif, 82, pp.240~251 (2012)
- Ceroni A, "DISULFIND:a disulfide bonding state and cysteine connectivity prediction server", Nucleic Acids Res, 34, pp.W177~W181 (2006)
- Chen JR, "Leukemia inhibitory factor can substitute for nidatory estrogen and is essential to inducing a receptive uterus for implantation but is not essential for subsequent embryogenesis", Endocrinology, 141, pp.4365~4372 (2000)
- Fairlie WD, "Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signaling", J. Biol. Chem, 279, pp.2125~2134 (2004)
- Fry RC, "The effect of leukaemia inhibitory factor (LIF)on embryogenesis", Reprod. Fertil. Dev, 4, pp.449~458 (1992)
- Gough NM, "The pleiotropic actions of leukemia inhibitory factor", Cancer Cells, 1, pp.77~80 (1989)
- Hannan NJ, "Models for study of human embryo implantation: choice of cell lines?", Biol. Reprod, 82, pp.235~245 (2010)
- Hudson KR, "Characterization of the receptor binding sites of human leukemia inhibitory factor and creation of antagonists", J. Biol. Chem, 271, pp.11971~11978 (1996)
- Imaizumi K, "Highlevel expression and efficient one-step chromatographic purification of a soluble human leukemia inhibitory factor (LIF) in Escherichia coli", Protein Expr. Purif, 90, pp.20~26 (2013)
- Lemons AR, "Birth control vaccine targeting leukemia inhibitory factor", Mol. Reprod. Dev, 79, pp.97~106 (2012)
- Liu SP, "n-Butylidenephthalide (BP) maintains stem cell pluripotency by activating Jak2", Stat3 pathway and increases the efficiency of iPS cells generation, 2012, pp.7, e44024~
- Menkhorst E, "Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice", PLoS One, 6, pp.e19665~ (2011)
- Metz S, "Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors", J. Biol. Chem, 283, pp.5985~5995 (2008)
- Mohamet L, "Determining the LIF-sensitive period for implantation using a LIF-receptor antagonist", Reproduction, 138, pp.827~836 (2009)
- Rassouli H, "Cloning, expression, and functional characterization of in-house prepared human leukemia inhibitory factor", Cell J, 15, pp.190~197 (2013)
- Renne C, "A new type of cytokine receptor antagonist directly targeting gp130", J. Biol. Chem, 273, pp.27213~27219 (1998)
- Robinson RC, "The crystal structure and biological function of leukemia inhibitory factor:implications for receptor binding", Cell, 77, pp.1101~1116 (1994)
- Schein CH, "Production of soluble recombinant proteins in bacteria", Nat. Biotechnol, 7, pp.1141~1149 (1989)
- Sengupta J, "Monoclonal anti-leukemia inhibitory factor antibody inhibits blastocyst implantation in the rhesus monkey", Contraception, 74, pp.419~425 (2006)
- Song JA, "Soluble expression of human leukemia inhibitory factor with protein disulfide isomerase in Escherichia coli and its simple purification", PLoS One, 8, pp.e83781~ (2013)
- Suman P, "LIF-STAT signaling and trophoblast biology", JAKSTAT, 2, pp.e25155~ (2013)
- Taupin JL, "Leukemia inhibitory factor: part of a large ingathering family", Int. Rev. Immunol, 16, pp.397~426 (1998)
- Terpe K., "Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems", Appl. Microbiol. Biotechnol, 60, pp.523~533 (2003)
- Upadhyay A, "Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes", Cytokine, 46, pp.332~338 (2009)
- Waugh DS, "Making the most of affinity tags", Trends Biotechnol, 23, pp.316~320 (2005)
- Weimar CH, "In-vitro model systems for the study of human embryo-endometrium interactions", Reprod. Biomed. Online, 27, pp.461~476 (2013)
- White CA, "Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy", Proc. Natl. Acad. Sci. USA, 104, pp.19357~19362 (2007)